File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia

TitleTherapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia
Authors
Lam, CCKMa, ESKKwong, YL
KeywordsFludarabine
MDS
Pancytopenia
t-AML
Issue Date2005
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/35105
Citation
American Journal Of Hematology, 2005, v. 79 n. 4, p. 288-290 How to Cite?
DOI: http://dx.doi.org/10.1002/ajh.20340
AbstractA 70-year-old man with B-cell chronic lymphocytic leukemia (CLL) received single-agent treatment with the purine analogue fludarabine, which led to complete remission. After 8 years, he presented with pancytopenia. Marrow examination showed acute myeloid leukemia (AML) with trilineage myelodysplasia (MDS). Cytogenetic analysis showed an unbalanced der(1;7)(p10;q10) that resulted effectively in deletion 7q; confirming the diagnosis of therapy-related AML (t-AML). No residual CLL was present. Together with previous reports of secondary cancers after fludarabine treatment and the association of monosomy 7/7q- with another purine analogue azathioprine, results suggest that t-AML might develop after fludarabine therapy. © 2005 Wiley-Liss, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/162870
ISSN
0361-8609
2023 Impact Factor: 10.1
2023 SCImago Journal Rankings: 2.607
ISI Accession Number ID
WOS:000230953100008
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorLam, CCKen_US
dc.contributor.authorMa, ESKen_US
dc.contributor.authorKwong, YLen_US
dc.date.accessioned2012-09-05T05:24:36Z-
dc.date.available2012-09-05T05:24:36Z-
dc.date.issued2005en_US
dc.identifier.citationAmerican Journal Of Hematology, 2005, v. 79 n. 4, p. 288-290en_US
dc.identifier.issn0361-8609en_US
dc.identifier.urihttp://hdl.handle.net/10722/162870-
dc.description.abstractA 70-year-old man with B-cell chronic lymphocytic leukemia (CLL) received single-agent treatment with the purine analogue fludarabine, which led to complete remission. After 8 years, he presented with pancytopenia. Marrow examination showed acute myeloid leukemia (AML) with trilineage myelodysplasia (MDS). Cytogenetic analysis showed an unbalanced der(1;7)(p10;q10) that resulted effectively in deletion 7q; confirming the diagnosis of therapy-related AML (t-AML). No residual CLL was present. Together with previous reports of secondary cancers after fludarabine treatment and the association of monosomy 7/7q- with another purine analogue azathioprine, results suggest that t-AML might develop after fludarabine therapy. © 2005 Wiley-Liss, Inc.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/35105en_US
dc.relation.ispartofAmerican Journal of Hematologyen_US
dc.subjectFludarabine-
dc.subjectMDS-
dc.subjectPancytopenia-
dc.subjectt-AML-
dc.subject.meshAcute Diseaseen_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic Agents - Administration & Dosage - Adverse Effects - Therapeutic Useen_US
dc.subject.meshBone Marrow - Pathologyen_US
dc.subject.meshChromosomes, Human, Pair 7en_US
dc.subject.meshHumansen_US
dc.subject.meshLeukemia, Lymphocytic, Chronic, B-Cell - Drug Therapyen_US
dc.subject.meshLeukemia, Myeloid - Chemically Induced - Genetics - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMonosomyen_US
dc.subject.meshNeoplasms, Second Primary - Chemically Induced - Genetics - Pathologyen_US
dc.subject.meshVidarabine - Administration & Dosage - Adverse Effects - Analogs & Derivatives - Therapeutic Useen_US
dc.titleTherapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemiaen_US
dc.typeArticleen_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/ajh.20340en_US
dc.identifier.pmid16044456-
dc.identifier.scopuseid_2-s2.0-23244433222en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-23244433222&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume79en_US
dc.identifier.issue4en_US
dc.identifier.spage288en_US
dc.identifier.epage290en_US
dc.identifier.isiWOS:000230953100008-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLam, CCK=16947291300en_US
dc.identifier.scopusauthoridMa, ESK=7202039934en_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US
dc.identifier.issnl0361-8609-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats